Serratia pneumonia is a lung infection caused by Serratia marcescens, a bacterium that overwhelmingly strikes hospitalized patients, particularly those on mechanical ventilators or with weakened immune systems. Treatment typically relies on broad-spectrum antibiotics such as carbapenems, fourth-generation cephalosporins, or fluoroquinolones, but the bacterium carries built-in resistance to many common drugs and has a growing tendency to acquire resistance to even last-resort antibiotics. That combination of vulnerability in the host and stubbornness in the organism makes Serratia pneumonia one of the more challenging hospital-acquired infections to manage.
The Bacterium Behind the Infection
Serratia marcescens is a rod-shaped, Gram-negative bacterium found in soil, water, and on surfaces throughout hospitals. It was once thought to be harmless and was even used as a tracer organism in biological experiments during the mid-twentieth century. That reputation has long since been discarded. The organism is now recognized as a significant cause of hospital-acquired infections, with a particular affinity for the lungs, urinary tract, and bloodstream of critically ill patients.1PubMed Central. The opportunistic pathogen Serratia marcescens utilizes type VI secretion to target bacterial competitors One of its most distinctive features is its ability to produce prodigiosin, a red pigment that can color the colonies a vivid red on laboratory plates and occasionally stain a patient’s sputum, creating the alarming appearance of coughing up blood when no bleeding is actually occurring.2PubMed Central. Pseudohemoptysis due to Serratia marcescens
Beyond its pigment, S. marcescens is armed with a range of tools that help it invade tissue and evade defenses. These include hemolysins (proteins that punch holes in host cells), enzymes that break down proteins, and iron-scavenging molecules called siderophores that steal a nutrient the bacterium needs to grow.3PubMed Central. Serratia marcescens: A Versatile Opportunistic Pathogen with Emerging Clinical and Biotechnological Significance – Section: Abstract It also forms biofilms readily, which are dense, sticky communities of bacteria that coat surfaces such as breathing tubes and catheters and are far harder to kill with antibiotics than free-floating bacteria.
How Serratia Damages the Lungs
Serratia pneumonia tends to be more destructive than many other bacterial pneumonias because the bacterium deploys several toxins that directly injure lung tissue. The best-studied is a pore-forming toxin called ShlA and its transport partner ShlB. In animal models, disabling ShlA dramatically reduced the weight loss, hemorrhage, and prolonged lung damage that Serratia pneumonia normally causes.4PubMed Central. Requirement for Serratia marcescens cytolysin in a murine model of hemorrhagic pneumonia This toxin is considered the bacterium’s dominant weapon, and its production is controlled by a signaling pathway that, when disrupted, can actually make the organism more aggressive rather than less, a quirk that complicates potential therapeutic strategies.5PubMed Central. RssAB-FlhDC-ShlBA as a major pathogenesis pathway in Serratia marcescens
Another key contributor is the serratia protease, an enzyme that, when introduced directly into the lungs of experimental animals, produces extensive fluid accumulation and bleeding that closely mirrors what happens in a living Serratia infection.6PubMed Central. Importance of serratia protease in the pathogenesis of experimental Serratia marcescens pneumonia – Section: Abstract The combination of cell-bursting hemolysin and tissue-dissolving protease helps explain why Serratia pneumonia is frequently hemorrhagic, meaning lung tissue bleeds into the airways, and why it can progress to abscess formation or spread into the bloodstream.
Who Gets Serratia Pneumonia
This is overwhelmingly a hospital infection, and within hospitals it clusters in intensive care units. Patients who develop it are typically elderly, with a median age approaching 69 in ICU studies, and the majority are male. The most consistently identified risk factors are mechanical ventilation, tracheostomy, central venous catheters, major surgery, and prolonged courses of antibiotics.7PubMed Central. Serratia marcescens in Intensive Care Units: Molecular Epidemiology, Biofilm-Mediated Persistence, Antimicrobial Resistance, and Genomic Surveillance – Section: 3. Molecular Epidemiology and Genomic Diversity in ICU-Associated S. marcescens In a study of a cardiothoracic ICU with a high rate of Serratia infections, multivariate analysis identified the length of ICU stay and tube feeding as independent risk factors, suggesting that the longer and more invasively a patient is managed, the greater the opportunity for the organism to gain a foothold.8PubMed. Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics
Community-acquired Serratia pneumonia, meaning infection picked up outside a hospital, is rare. In a study of over 900 community-acquired pneumonia cases, only a single case was attributed to S. marcescens.9SpringerLink / European Journal of Clinical Microbiology & Infectious Diseases. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli When pneumonia from Gram-negative bacteria did occur in the community, the mortality rate was roughly three times higher than for other types of pneumonia, and the Gram-negative cause itself was an independent risk factor for dying. So while Serratia pneumonia is almost always a hospital problem, the broader family of Gram-negative pneumonias carries serious consequences even outside ICUs.
What Serratia Pneumonia Looks Like
The symptoms of Serratia pneumonia are not dramatically different from other bacterial pneumonias: fever, cough, difficulty breathing, and declining oxygen levels. What sets it apart is the imaging pattern and the tendency toward hemorrhage. In a radiological review of 25 patients, the most common finding was patchy bronchopneumonia (about half of cases), followed by diffuse, uneven infiltrates throughout both lungs (about two-fifths). Small clear areas within the infected zones, suggesting early tissue breakdown, appeared in a fifth of patients, and one patient developed a large lung abscess. Fluid collection around the lung (pleural effusion) was seen in roughly a quarter of cases.10PubMed. Serratia pneumonia
Clinicians should also be aware of pseudohemoptysis: red-tinged sputum that looks like blood but is actually caused by the prodigiosin pigment produced by the bacterium.2PubMed Central. Pseudohemoptysis due to Serratia marcescens Recognizing this phenomenon can prevent unnecessary invasive workups for what appears to be bleeding but is really a harmless byproduct of bacterial colonization. Not all Serratia strains produce the pigment, but when they do, the visual effect can be quite striking.
Diagnosing the Infection
Confirming Serratia pneumonia starts with standard respiratory cultures from sputum, bronchoalveolar lavage, or endotracheal aspirate. The organism grows readily on standard laboratory media and is identifiable by automated systems. In recent years, MALDI-TOF mass spectrometry has become the standard rapid identification method in many hospitals, giving species-level identification within minutes from a colony.11JAC-Antimicrobial Resistance. Serratia marcescens enzyme SME-2 isolated from sputum in New Zealand – Section: Methods During outbreak investigations, this technology can even help distinguish between different strains circulating in a unit, with results that largely match more detailed genomic typing when appropriate similarity thresholds are used.12PubMed. Use of MALDI-TOF mass spectrometry to detect nosocomial outbreaks of Serratia marcescens and Citrobacter freundii
Once the organism is identified, the critical next step is antibiotic susceptibility testing, because the range of drugs that might or might not work against a given Serratia isolate varies enormously. Whole-genome sequencing is increasingly used alongside traditional susceptibility testing, especially when carbapenem resistance is suspected, because it can pinpoint the specific resistance genes the isolate carries and guide treatment decisions more precisely.
Why Serratia Is Inherently Hard to Treat
Serratia marcescens arrives at the clinical encounter already resistant to several commonly used antibiotics. It naturally produces a chromosomal AmpC beta-lactamase enzyme that breaks down many penicillins and older cephalosporins. This means that ampicillin, ampicillin-sulbactam, and second-generation cephalosporins like cefuroxime are essentially useless against it, with resistance rates reaching 100% in studies.13PubMed Central. Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis – an observational study – Section: RESULTS This is not acquired resistance that comes and goes; it is a built-in feature of the species.
The problem escalates when the chromosomal AmpC enzyme is produced in excess. Mutations that ramp up AmpC production can push resistance to third-generation cephalosporins and even carbapenems, which are normally the backbone of treatment. In one outbreak, meropenem-resistant isolates were found to be producing AmpC at 87 to 156 times the normal level, and the loss of a channel protein in the bacterial outer membrane further blocked drug entry.14PubMed Central. Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss This kind of resistance can develop during a course of treatment, which is why clinicians sometimes see an infection initially respond to a drug and then stop responding a few days later.
The Growing Threat of Carbapenem Resistance
Carbapenems like meropenem and imipenem have long been considered the heavy artillery against Serratia infections, reserved for when other drugs fail. But Serratia strains capable of destroying carbapenems are appearing with increasing frequency. The first well-characterized example was IMP-1, a metallic beta-lactamase enzyme that could break down carbapenems and virtually all other beta-lactam antibiotics.15PubMed Central. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance Since then, strains carrying multiple carbapenem-destroying genes have emerged. A recent report described an isolate carrying three different resistance genes simultaneously, leaving it resistant to nearly every class of antibiotic except tigecycline.16PubMed Central. Emergence of carbapenem-resistant Serratia marcescens co-harboring blaNDM-1, blaKPC-2, and blaSRT-2 in bloodstream infection – Section: Abstract
These resistance genes often sit on mobile genetic elements (plasmids) that can jump between bacterial species, meaning the problem is not confined to Serratia alone. Hospital sink drains have been identified as persistent reservoirs of carbapenemase-carrying Serratia clones, with the same resistant strains surviving in plumbing for years and seeding new infections whenever conditions allow.
Treatment Approaches for Susceptible Strains
When a Serratia isolate is susceptible to standard drugs, the fourth-generation cephalosporin cefepime is a strong option. In an observational study of pneumonia patients, S. marcescens showed no resistance to cefepime, in sharp contrast to its total resistance to ampicillin-based drugs.13PubMed Central. Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis – an observational study – Section: RESULTS Fluoroquinolones, trimethoprim-sulfamethoxazole, and carbapenems are also commonly used, depending on the susceptibility profile. A retrospective study of bloodstream infections caused by cephalosporin-resistant S. marcescens found that carbapenem-sparing regimens, particularly piperacillin-tazobactam and fluoroquinolones, produced similar 14-day mortality rates to carbapenems in patients whose isolates tested susceptible to those alternatives.17Journal of Microbiology, Immunology and Infection. Outcomes associated with carbapenem-sparing versus carbapenem-containing therapy for third-generation cephalosporin non-susceptible Serratia marcescens bacteremia: a retrospective cohort analysis – Section: Results
The ability to avoid carbapenems when alternatives work matters, because every unnecessary carbapenem prescription accelerates the development of carbapenem resistance in the hospital environment. If susceptibility testing shows that a narrower-spectrum drug will do the job, most infectious disease specialists will prefer it.
Combination Therapy Versus a Single Drug
Whether to use one antibiotic or two simultaneously for serious Serratia infections remains genuinely unsettled. In a study focused on Serratia endocarditis (heart valve infection, not pneumonia, but relevant because it represents deep-seated Serratia disease), combination therapy was associated with lower rates of persistent infection (0% versus 15%) and lower 90-day mortality (about 11% versus 31%) compared to monotherapy.18PubMed Central. Serratia endocarditis: antimicrobial management strategies and clinical outcomes – Section: Results The trade-off was more side effects requiring drug discontinuation in the combination group.
But these results do not translate straightforwardly to pneumonia or bloodstream infection. A separate analysis of cephalosporin-resistant Gram-negative bacteremia, including Serratia species, found no significant mortality difference between monotherapy and combination therapy, and the mortality rate was actually numerically lower in the monotherapy group.19PubMed. Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species These conflicting findings reflect a broader reality in infectious disease: the value of combination therapy depends heavily on the site of infection, the severity of illness, and the specific resistance profile of the isolate. For carbapenem-resistant strains, where treatment options are already scarce, combinations are used more often out of necessity than proven superiority.
Newer Drugs for Resistant Strains
When standard drugs fail, a newer generation of beta-lactam/beta-lactamase inhibitor combinations has expanded the options. Ceftazidime-avibactam showed potent laboratory activity against S. marcescens, achieving susceptibility rates above 99% even among isolates that were resistant to standard ceftazidime.20PubMed. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014) Meropenem-vaborbactam, another newer combination, successfully treated a hemodialysis patient with carbapenem-resistant Serratia bacteremia when used as monotherapy in a published case report.21Journal of Antimicrobial Chemotherapy. Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient
These agents are not universally effective. Ceftazidime-avibactam works well against KPC-type and AmpC-type resistance but does not cover metallo-beta-lactamases like IMP-1 or NDM-1, which require different drug combinations. So knowing exactly which resistance mechanism a strain carries, whether through genomic testing or targeted phenotypic assays, directly determines which of these newer drugs can be used. The era of “this antibiotic works for Serratia” as a general statement is over. Every isolate needs its own answer.
Serratia in Neonatal Intensive Care
Newborns, especially premature infants, are a uniquely vulnerable population for Serratia infections. In neonatal intensive care units, S. marcescens causes a range of problems from conjunctivitis and urinary infections to pneumonia, bloodstream infection, and meningitis, with bloodstream infection being the most common site followed by the respiratory tract.22PubMed Central. Serratia marcescens Infections in Neonatal Intensive Care Units (NICUs) – Section: Abstract Outbreaks in NICUs tend to be devastating. In one report, five preterm infants born between 25 and 30 weeks of gestation were affected, two developed septicemia that proved fatal, and only two were colonized without signs of infection.23PubMed. Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature
A six-month outbreak in another NICU affected 18 children with an overall attack rate of 12% and a case fatality rate of about 24% among those in intensive care. Pneumonia and conjunctivitis were tied as the most common presentations, each accounting for six cases.24PubMed. A six-month Serratia marcescens outbreak in a Neonatal Intensive Care Unit – Section: RESULTS These outbreaks are difficult to contain because Serratia survives well on surfaces and in wet environments, including soap dispensers, breast-pump equipment, and sink drains. Stopping transmission typically requires aggressive environmental cleaning, cohorting of infected and colonized infants, strict hand hygiene enforcement, and sometimes temporary unit closure.
The Hospital Sink Problem
One of the more frustrating aspects of Serratia control in hospitals is the role of the built environment, particularly water fixtures. Sink drains in ICUs have been shown to harbor persistent Serratia clones for years, including strains carrying carbapenemase genes on mobile plasmids. A study combining epidemiological data from over 1,400 Serratia isolates collected from ICU sinks with genomic analysis of outbreak strains found that the same clones persisting in sinks were genetically related to strains causing patient infections, and that carbapenemase-carrying plasmids circulated between sink bacteria and clinical isolates.25PubMed Central. The ICU environment contributes to the endemicity of the “Serratia marcescens complex” in the hospital setting
This creates a cycle that is hard to break. Even after an outbreak is apparently controlled through patient-level interventions, the organism persists in plumbing and can re-emerge months or years later. Some hospitals have responded by redesigning sink placement to increase distance from patient beds, installing waterless hand-hygiene stations, or using specialized drain disinfection protocols. The evidence on which of these interventions works best is still evolving, but the recognition that the environment is not just a passive bystander but an active reservoir has changed how infection-control teams approach Serratia outbreaks.
Red Sputum and the Legacy of a “Harmless” Bacterium
The prodigiosin pigment that gives some S. marcescens strains their red color has a long and colorful history. Medieval accounts of “bleeding bread” and similar phenomena are now widely attributed to Serratia growing on starchy substrates in warm, humid conditions. Through much of the twentieth century, the organism’s supposed harmlessness made it a popular tool for tracking airflow in hospitals and even in open-air biological warfare experiments. The U.S. military famously released S. marcescens over San Francisco in the 1950s to simulate a bioweapon attack, an experiment that has since become a case study in bioethics.
In modern clinical practice, the pigment occasionally causes pseudohemoptysis, where a patient’s sputum appears blood-tinged or frankly red despite no actual pulmonary hemorrhage.2PubMed Central. Pseudohemoptysis due to Serratia marcescens Clinicians who are unfamiliar with this phenomenon may order bronchoscopies, CT angiograms, or other invasive tests searching for a bleeding source that does not exist. Awareness of pseudohemoptysis is especially relevant in ventilated patients who are colonized with pigmented Serratia strains in their airways. If cultures grow S. marcescens and the “blood” is uniformly red without the clotting or brownish discoloration typical of true hemoptysis, pseudohemoptysis should be considered before escalating the workup.